[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @Heatlamp11 Lidopete Lidopete posts on X about $mreo, $rare, university of, ticker the most. They currently have XXX followers and XXX posts still getting attention that total XX engagements in the last XX hours. ### Engagements: XX [#](/creator/twitter::27276246/interactions)  - X Week XXXXX -XX% - X Month XXXXX -XX% - X Months XXXXXX +322% - X Year XXXXXX +412% ### Mentions: X [#](/creator/twitter::27276246/posts_active)  - X Week X -XX% - X Month XX -XX% - X Months XX +207% - X Year XXX +528% ### Followers: XXX [#](/creator/twitter::27276246/followers)  - X Week XXX +1.90% - X Month XXX +3.60% - X Months XXX +29% - X Year XXX +35% ### CreatorRank: undefined [#](/creator/twitter::27276246/influencer_rank)  ### Social Influence [#](/creator/twitter::27276246/influence) --- **Social category influence** [cryptocurrencies](/list/cryptocurrencies) [stocks](/list/stocks) [finance](/list/finance) **Social topic influence** [$mreo](/topic/$mreo) #2, [$rare](/topic/$rare) #19, [university of](/topic/university-of), [ticker](/topic/ticker) **Top assets mentioned** [SuperRare (RARE)](/topic/$rare) ### Top Social Posts [#](/creator/twitter::27276246/posts) --- Top posts by engagements in the last XX hours "6:51 AM THE FLY $MREO $RARE Ultragenyx placed on 'Positive Catalyst Watch' at JPMorgan JPMorgan analyst Anupam Rama placed shares of Ultragenyx on "Positive Catalyst Watch" ahead of the company's ORBIT and COSMIC study updates. The firm has confidence in setrusumab's clinical success and keeps an Overweight rating on the shares with a $XXX price target. At current share levels JPMorgan sees a "very positive" reward/risk profile heading into the updates with more win scenarios than downside scenarios" [X Link](https://x.com/Heatlamp11/status/1973726987144384571) [@Heatlamp11](/creator/x/Heatlamp11) 2025-10-02T12:29Z XXX followers, 1301 engagements "$MREO & $RARE third-party presenters will be at a meeting this week featuring Osteogenesis Imperfecta (O.I.) trials specifically on October XX 2025. The OIFE (Osteogenesis Imperfecta Federation Europe) Clinical Trial Update webinar scheduled for October XX will include updates on the Orbit and Cosmic studies. October XX O.I. Meeting Details: The OIFE Clinical Trial Update 2025 takes place on October XX 2025. It covers ongoing O.I. trials including the Orbit and Cosmic studies (Mereo/Ultragenyx). In summary key O.I. trial updates will be shared at the OIFE meeting this week specifically on" [X Link](https://x.com/Heatlamp11/status/1977734466656215150) [@Heatlamp11](/creator/x/Heatlamp11) 2025-10-13T13:53Z XXX followers, XXX engagements "That's phenomenal I'm very much looking forward to the report. Thanks for digging. Also if any help Mrs. Heike HoyerKuhn a pediatric bone disease specialist at the University of Cologne remains an active and prominent contributor to the Setrusumab (UX143) research program for osteogenesis imperfecta (OI) including both the COSMIC and ORBIT studies. Recent updates confirm her ongoing involvement in related clinical and translational OI research through 2025. Role and Research: Mrs. HoyerKuhn is one of the European investigators collaborating on the global COSMIC and ORBIT trials sponsored by" [X Link](https://x.com/Heatlamp11/status/1978808055157379105) [@Heatlamp11](/creator/x/Heatlamp11) 2025-10-16T12:59Z XXX followers, XX engagements "AI Generated-Recent comments from $MREO & $RARE: As of mid to late 2025 Ultragenyx Pharmaceutical (ticker: RARE) in collaboration with Mereo BioPharma (MREO) has made several official comments regarding their Setrusumab (UX143) program for osteogenesis imperfecta (OI). JulyAugust 2025 Updates: In July and August 2025 Ultragenyx (RARE) and Mereo confirmed that both Phase X trialsORBIT (ages 525) and COSMIC (ages 27)are proceeding smoothly and remain on track for final analyses around yearend 2025. Both companies acknowledged that the interim analysis did not meet the statistical threshold for" [X Link](https://x.com/Heatlamp11/status/1978813061545750914) [@Heatlamp11](/creator/x/Heatlamp11) 2025-10-16T13:19Z XXX followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@Heatlamp11 Lidopete
Lidopete posts on X about $mreo, $rare, university of, ticker the most. They currently have XXX followers and XXX posts still getting attention that total XX engagements in the last XX hours.
Engagements: XX #
- X Week XXXXX -XX%
- X Month XXXXX -XX%
- X Months XXXXXX +322%
- X Year XXXXXX +412%
Mentions: X #
- X Week X -XX%
- X Month XX -XX%
- X Months XX +207%
- X Year XXX +528%
Followers: XXX #
- X Week XXX +1.90%
- X Month XXX +3.60%
- X Months XXX +29%
- X Year XXX +35%
CreatorRank: undefined #
Social Influence #
Social category influence cryptocurrencies stocks finance
Social topic influence $mreo #2, $rare #19, university of, ticker
Top assets mentioned SuperRare (RARE)
Top Social Posts #
Top posts by engagements in the last XX hours
"6:51 AM THE FLY $MREO $RARE Ultragenyx placed on 'Positive Catalyst Watch' at JPMorgan JPMorgan analyst Anupam Rama placed shares of Ultragenyx on "Positive Catalyst Watch" ahead of the company's ORBIT and COSMIC study updates. The firm has confidence in setrusumab's clinical success and keeps an Overweight rating on the shares with a $XXX price target. At current share levels JPMorgan sees a "very positive" reward/risk profile heading into the updates with more win scenarios than downside scenarios"
X Link @Heatlamp11 2025-10-02T12:29Z XXX followers, 1301 engagements
"$MREO & $RARE third-party presenters will be at a meeting this week featuring Osteogenesis Imperfecta (O.I.) trials specifically on October XX 2025. The OIFE (Osteogenesis Imperfecta Federation Europe) Clinical Trial Update webinar scheduled for October XX will include updates on the Orbit and Cosmic studies. October XX O.I. Meeting Details: The OIFE Clinical Trial Update 2025 takes place on October XX 2025. It covers ongoing O.I. trials including the Orbit and Cosmic studies (Mereo/Ultragenyx). In summary key O.I. trial updates will be shared at the OIFE meeting this week specifically on"
X Link @Heatlamp11 2025-10-13T13:53Z XXX followers, XXX engagements
"That's phenomenal I'm very much looking forward to the report. Thanks for digging. Also if any help Mrs. Heike HoyerKuhn a pediatric bone disease specialist at the University of Cologne remains an active and prominent contributor to the Setrusumab (UX143) research program for osteogenesis imperfecta (OI) including both the COSMIC and ORBIT studies. Recent updates confirm her ongoing involvement in related clinical and translational OI research through 2025. Role and Research: Mrs. HoyerKuhn is one of the European investigators collaborating on the global COSMIC and ORBIT trials sponsored by"
X Link @Heatlamp11 2025-10-16T12:59Z XXX followers, XX engagements
"AI Generated-Recent comments from $MREO & $RARE: As of mid to late 2025 Ultragenyx Pharmaceutical (ticker: RARE) in collaboration with Mereo BioPharma (MREO) has made several official comments regarding their Setrusumab (UX143) program for osteogenesis imperfecta (OI). JulyAugust 2025 Updates: In July and August 2025 Ultragenyx (RARE) and Mereo confirmed that both Phase X trialsORBIT (ages 525) and COSMIC (ages 27)are proceeding smoothly and remain on track for final analyses around yearend 2025. Both companies acknowledged that the interim analysis did not meet the statistical threshold for"
X Link @Heatlamp11 2025-10-16T13:19Z XXX followers, XXX engagements